Expected Moves

CervoMed is expected to present initial 12-week biomarker data from its Phase 2a trial evaluating neflamapimod in nonfluent variant primary progressive aphasia (nfvPPA) at the ISFTD conference.

Scheduled Q3 2026 earnings print. Investors will evaluate operating expenses against the 24.9 million cash balance and look for management commentary heading into CTAD.

Full 12-week and initial 24-week biomarker data presentations for neflamapimod in nfvPPA at the 19th Clinical Trials on Alzheimer's Disease (CTAD) conference.

Topline 24-week clinical outcomes from the Phase 2a trial of neflamapimod in nfvPPA, testing for measurable cognitive and functional benefit.

Management's stated goal is securing a strategic partner to fund the Phase 3 Dementia with Lewy Bodies (DLB) trial before the Q3 2027 cash runway expires.

Expected initiation and first patient dosing of the Phase 2a trial for neflamapimod in ALS via the UK-based EXPERTS-ALS platform.

Estimated Q4 2026 earnings report, serving as the final operational update before critical Phase 2a nfvPPA clinical outcomes.